A Vancouver company will soon be dosing patients in a new clinical study aimed at benefitting people who have suffered the negative neurological impact of strokes.

On Monday, Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) announced that it had received approval to conduct a phase 1 clinical study examining an intravenous formulation of DMT (designated as AP-188) for the treatment of ischemic stroke.

The new study was approved by the Stichting Beoordeling Ethiek Biomedisch Onderzoek (Foundation for the Assessment of Ethics of Biomedical Research, known as BEBO), an independent medical research ethics committee. The trial will be held at the Centre for Human Drug Research (CHDR) in the city of Leiden, Netherlands…

Full story at: https://mugglehead.com/algernon-receives-approval-to-conduct-dmt-study-in-the-netherlands/